LVTX Live signals | Maximize Profits with Getagraph.com

SELL 100901 min ago

@ $1.749

Issued: 9 Feb 2024 @ 10:59

Return: 56.65%

Previous signal: Feb 8 - 15:16

Previous signal: Buy

Return: 5.05 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 13:39):

Stats
Today's Volume	106 823
Average Volume	1.85M
Market Cap	72.03M
EPS	$0 ( 2024-04-09 )
Next earnings date	( $-0.250 ) 2024-06-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.750
ATR14	$0.0160 (0.58%)

Volume Correlation

Long: -0.07 (neutral)

Short: 0.27 (neutral)

Signal:(48.644) Neutral

Lava Therapeutics B.V. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lava Therapeutics B.V. Correlation - Currency/Commodity

-0.78
( moderate negative )

-0.82
( strong negative )

0.00
( neutral )

0.45
( neutral )

-0.75
( moderate negative )

0.81
( strong )

Lava Therapeutics B.V. Financials

Annual	2023
Revenue:	$6.77M
Gross Profit:	$3.29M (48.56 %)
EPS:	$-1.570

Q4	2023
Revenue:	$352 999
Gross Profit:	$198 999 (56.37 %)
EPS:	$-0.240

Q3	2023
Revenue:	$53 000.00
Gross Profit:	$43 000.00 (81.13 %)
EPS:	$-0.340

Q2	2023
Revenue:	$5.14M
Gross Profit:	$2.75M (53.53 %)
EPS:	$-0.480

Financial Reports:

No articles found.

Lava Therapeutics B.V.

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.